What is the 13F Pro Quality Score for ENTA?

13F Pro ranks ENANTA PHARMACEUTICALS INC (ENTA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ENTA's current score at https://13fpro.ai/research/ENTA (free sign-up required for the full ranking).

Where does 13F Pro source ENTA data?

All ENANTA PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. ENANTA PHARMACEUTICALS INC files with the SEC under CIK 1177648. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ENTA in?

ENANTA PHARMACEUTICALS INC (ENTA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ENTA research updated on 13F Pro?

ENTA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ENANTA PHARMACEUTICALS INC(ENTA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1177648 ENTA stock profile & AI dashboard →

13F Pro Quality Score

15.5/100

Rank #2,746 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

18.9/100

Profitability

7.6/100

Balance Sheet

10.3/100

Earnings Quality

30.0/100

Free Cash Flow

10.7/100

Institutional Flow

61.9/100

Revenue Scale

14.1/100

Dilution Risk

6.7/100

ENTA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ENANTA PHARMACEUTICALS INC (ENTA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ENTA at 15.5/100 on a 32-signal composite quality model, placing it at rank #2,746 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (7.6) and balance sheet strength (10.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ENANTA PHARMACEUTICALS INC reports quarterly revenue of $17.2M, net income of $-13.1M, free cash flow of $-7.2M. Top institutional holders of ENTA by reported 13-F value include JANUS HENDERSON GROUP PLC, BlackRock,, FARALLON CAPITAL MANAGEMENT, based on the most recent SEC filings. ENTA trades on the Nasdaq exchange and files with the SEC under CIK 1177648. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ENANTA PHARMACEUTICALS INC directly from SEC EDGAR. ENANTA PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 8 and 41 since 2021, currently 15.5 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about ENANTA PHARMACEUTICALS INC

Quirks, history, and lore behind ENTA — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. biopharmaceutical company · listed on Nasdaq · headquartered in Massachusetts · focused on infectious disease.
2
The Numbers
With a market cap in the low hundreds of millions and no commercial product revenue of its own, it survives largely on collaboration income from a larger pharma partner.
3
The History
Founded in the early 2000s, the company built its pipeline around macrocyclic chemistry — a specialized drug-design approach that helps target slippery viral proteins.
4
The Secret
Its biggest commercial win wasn't even sold under its own name — a key compound it developed ended up inside AbbVie's blockbuster hepatitis C regimen, generating royalty-style payments.
5
The Lore
After the hepatitis C market cratered faster than anyone expected, the company pivoted hard toward RSV and COVID antivirals, betting its future on the next respiratory menace.
6
The Giveaway
This Watertown, MA biotech supplied chemistry brainpower behind Mavyret and now chases its own antiviral glory under the ticker ENTA.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$17.2M

Net Income

Q2 2026

$-13.1M

Free Cash Flow

Q2 2026

$-7.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-17.5% YoY

$65.3MFY 2025

FY21 $97.1MFY22 $86.2MFY23 $79.2MFY25 $65.3M

Net Income

+38.8% YoY

$-81.9MFY 2025

FY21 $-79.0MFY22 $-121.8MFY23 $-133.8MFY25 $-81.9M

Operating Income

+37.8% YoY

$-85.3MFY 2025

FY21 $-109.6MFY22 $-123.8MFY23 $-137.2MFY25 $-85.3M

EPS (Diluted)

+39.8% YoY

$-3.84FY 2025

FY21 $-3.92FY22 $-5.91FY23 $-6.38FY25 $-3.84

Total Assets

-39.3% YoY

$280.7MFY 2025

FY21 $438.8MFY22 $375.4MFY23 $462.3MFY25 $280.7M

Op. Cash Flow

+81.3% YoY

$-19.3MFY 2025

FY21 $-70.0MFY22 $-84.8MFY23 $-103.2MFY25 $-19.3M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$65.3M -17.5%	$79.2M -8.1%	$86.2M -11.2%	$97.1M -20.7%	$122.5M -40.7%	$206.6M
Net Income	$-81.9M +38.8%	$-133.8M -9.9%	$-121.8M -54.1%	$-79.0M -118.4%	$-36.2M -150.3%	$72.0M
Operating Income	$-85.3M +37.8%	$-137.2M -10.8%	$-123.8M -13.0%	$-109.6M -163.1%	$-41.6M -147.1%	$88.3M
EPS (Diluted)	$-3.84 +39.8%	$-6.38 -8.0%	$-5.91 -50.8%	$-3.92 -116.6%	$-1.81 -152.0%	$3.48
Total Assets	$280.7M -39.3%	$462.3M +23.1%	$375.4M -14.4%	$438.8M -9.7%	$486.1M +17.4%	$414.2M
Operating Cash Flow	$-19.3M +81.3%	$-103.2M -21.7%	$-84.8M -21.1%	$-70.0M -1087.5%	$7.1M -75.7%	$29.2M

AI Insight: ENTA Financial Trends

Operating losses narrowing but revenue stalled at ~$15–19M; equity eroding despite Q4 2025 recovery.

• Operating loss improved from $-30M (Q3 2024) to $-12M (Q1 2026), a 60% reduction over 6 quarters.

• Net loss contracted from $-29M (Q3 2024) to $-13M (Q1 2026); trend toward breakeven accelerating.

• Equity declined from $149M (Q2 2024) to $117M (Q1 2026), a 21% erosion despite operating improvement.

⚠ Revenue flat/volatile at $15–19M range; no growth signal. Q1 2026 revenue $17M vs Q1 2025 unavailable.

⚠ Operating cash flow inconsistent: positive $18M (Q2 2025) but negative last three quarters; uncertainty.

⚠ Equity spike to $127M (Q4 2025) reversed sharply to $117M (Q1 2026); sustainability in question.

AI Insight: ENTA Ratio Trends

Operating margin improved 18.3 percentage points from Q3 2025 to Q1 2026, but the company remains deeply unprofitable across all efficiency metrics.

• Operating margin recovered to -69.1% in Q1 2026 from -121.6% in Q3 2025, a significant sequential improvement.

• ROA improved to -16.6% in Q1 2026 from -26.6% in Q3 2025, suggesting better near-term asset utilization.

• All profitability metrics remain deeply negative; NPM at -76.3% and ROE at -44.9% in Q1 2026.

⚠ Q1 2025 data missing entirely; limits visibility into recent operational trends and potential seasonal patterns.

⚠ Despite margin recovery, company still burning capital with negative ROE, ROA, and ROIC across all recent periods.

Get alerted when ENTA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ENANTA PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ENTA

JANUS HENDERSON GROUP PLC
$47.7M3,784,055 sh
BlackRock, Inc.
$39.2M3,103,768 sh
FARALLON CAPITAL MANAGEMENT LLC
$36.3M2,871,862 sh
Deep Track Capital, LP
$24.7M1,956,867 sh
VANGUARD CAPITAL MANAGEMENT LLC
$14.9M1,178,049 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$12.0M948,904 sh
Spruce Street Capital LP
$11.8M932,598 sh
MILLENNIUM MANAGEMENT LLC
$11.1M882,097 sh
GEODE CAPITAL MANAGEMENT, LLC
$9.2M725,061 sh
RENAISSANCE TECHNOLOGIES LLC
$8.4M665,258 sh

Fund	Value	Shares
JANUS HENDERSON GROUP PLC	$47.7M	3,784,055
BlackRock, Inc.	$39.2M	3,103,768
FARALLON CAPITAL MANAGEMENT LLC	$36.3M	2,871,862
Deep Track Capital, LP	$24.7M	1,956,867
VANGUARD CAPITAL MANAGEMENT LLC	$14.9M	1,178,049
VANGUARD PORTFOLIO MANAGEMENT LLC	$12.0M	948,904
Spruce Street Capital LP	$11.8M	932,598
MILLENNIUM MANAGEMENT LLC	$11.1M	882,097
GEODE CAPITAL MANAGEMENT, LLC	$9.2M	725,061
RENAISSANCE TECHNOLOGIES LLC	$8.4M	665,258

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ENTA on your watchlist

Track score changes the day ENANTA PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ENTA a good stock to buy?

13F Pro's AI-powered analysis of ENANTA PHARMACEUTICALS INC (ENTA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENTA are available on the ENTA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ENTA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENTA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ENANTA PHARMACEUTICALS INC's investment landscape.